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ABSTRACT
Succinate Dehydrogenase-B (SDH-B) gene mutations constitute one of the most frequent forms 
of hereditary paragangliomas (PGL). Genetic study is advised in all cases for the evaluation 
of tumour behaviour, the selection of optimal management and the surveillance of the first 
degree relatives. There are limited data on the genetic characteristics of patients with PGLs 
from Middle East countries, and to our knowledge this is the first study from Iran. We present 
the clinical and genetic characteristics of a 29-year old woman who presented with hypertension 
secondary to a para-aortic PGL. She was shown to have a novel mutation in the SDH-B gene 
and her family was subsequently screened. We also emphasize the problems in diagnosing and 
treating patients in this region.
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Case report
IntroductIon
Phaeochromocytomas (PCC) and paragangliomas 
(PGL) are neuroendocrine tumours arising from 
chromaffin cells of the adrenal medulla or extra-
adrenal sympathetic or parasympathetic ganglia, 
respectively. The incidence of these tumours is ap-
proximately 2-8 per million population per year, with 
extra-adrenal tumours comprising some 10-20% of 
the cases. Mostly, the term phaeochromocytoma is 
used for all catecholamine-secreting tumours located 
either in adrenal or in extra-adrenal locations, while 
the term  paraganglioma is used only for head-and-
neck tumours originating from the parasympathetic 
system. Several authors, however, restrict the term 
PCC to specifically adrenal tumours and label all 
others as extra-adrenal PGLs.1,2 Most PGLs are 
located in the abdominal or pelvic region and may 
present with severe hypertension due to the secre-
tion of large amounts of adrenaline or noradrena-
Figure 1. Abdominal CT scan showing the right sided para aor-
tic tumour.
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line from the tumour. PGLs develop as sporadic or 
hereditary forms, but germline mutations are now 
considered to be responsible for some 30-40% of 
patients presenting with phaeochromocytomas and 
50% of those with paragangliomas. Mutation in the 
succinate dehydrogenase-B gene (SDH-B), which 
encodes for subunit B of the complex enzyme, has 
been shown to be one of the most prevalent forms of 
the hereditary variants of PGL, with a high rate of ma-
lignant transformation.3,4 There are only very limited 
reports on hereditary forms of PGLs in countries of 
the Middle East, and this is the first study addressing 
the clinical and genetic characteristics of an Iranian 
family harbouring a novel SDH-B mutation.
Case presentation
A 29-year old woman was referred to Taleghani 
General Hospital, Tehran, Iran, in 2011 because of 
persistent headache and palpitations for the previous 
6 years which had recently deteriorated. Her past his-
tory was positive for a single episode of severe arterial 
hypertension (blood pressure 270/110mmHg) that was 
incidentally discovered during maxillo-facial surgery 
5 years previously. The surgery was cancelled and 
evaluation of the patient revealed high 24h urinary 
metanephrine (800μg/24h, normal <440μg/day) and 
24h VMA (17mg/day, normal <12mg/day) excretion, 
but with reported normal abdominal MRI and CT 
scans. The patient refused further evaluation and was 
discharged on combined adrenoceptor blockade with 
prazosin and atenolol. Five months prior to admis-
sion she was seen at another hospital for increasing 
headache and palpitations: an abdominal CT scan 
showed a para-aortic tumour. She underwent a per-
cutaneous needle biopsy and the mass was diagnosed 
as a paraganglioma. She was referred to our hospital 
for further evaluation.
On physical examination her blood pressure was 
170/110mmHg and heart rate was 110 beats per 
minute: the rest of the physical examination was 
negative. Routine laboratory evaluations were nor-
mal except for mild normocytic anaemia. Laboratory 
evaluation revealed high 24h urine VMA (20.3mg/
day, normal <12) and normetanephrine (3000μg/day, 
normal <440). Abdominal CT and an MRI showed a 
lobulated 3cm round mass in the para-aortic region 
(Figure 1, black arrows).
After appropriate management of her hyperten-
sion with modification to her α- and β-adrenoceptor 
blockade, she underwent surgery and a solitary 4 by 3.5 
by 2.5 cm mass located in the para-aortic region with 
an associated enlarged lymph node were removed. 
Histopathologic evaluation revealed a well-encapsu-
lated tumour with a reddish-brown fleshy cut surface. 
The cells were bound with a delicate highly vascular 
fibrous stroma and arranged in well-defined nests 
or zellballen pattern. The tumoural cells had finely 
granular cytoplasm, round nuclei and prominent nu-
cleoli (Figure 2A). Immunohistochemistry evaluation 
revealed positive staining for chromogranin A in the 
tumour cells, positive S100 in the sustentacular cells, 
a Ki-67 of 1% and negative staining for cytokeratin 
in the tumour cells (Figure 2B). The lymph node was 
free of tumour. The histopathologic diagnosis was of 
a paraganglioma.
Genetic analysis in Oxford on DNA samples 
prepared from the peripheral white cells revealed a 
heterozygous 3-nucleotide deletion, c.596-598 delACT 
(p.Tyr199del) in exon 6.
The patient’s post-operative course was unevent-
ful. Her blood pressure normalised after surgery and 
the patient was discharged from hospital after 5 days. 
On her last examination, one year after surgery, she 
had mild diastolic hypertension (130/100 mmHg) 
on atenolol 50 mg and hydrochlorothiazide 25 mg/
day without any signs or symptoms of catecholamine 
excess, and her urinary metanephrine excretion had 
normalised.
Figure 2B. Nests of tumoural cells strongly immunoreactive to 
chromogranin A (immunoperoxidase stain for chromogranin 
A×100).
Figure 3. Pedigree of the family.
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Figure 2A. Characteristic nesting pattern of tumour cells (H&E 
×100).
The patient was the offspring of a consanguineous 
marriage, her parents being cousins on the maternal 
side. First-degree family members including her fa-
ther, mother, three brothers and three sisters were 
also assessed. Both parents were hypertensive, 160/90 
mmHg and 170/120 mmHg, but had no symptoms 
suggestive of catecholamine excess; no other family 
member agreed to clinical examination and none 
to biochemical assessment. However, all agreed to 
genetic analysis and the same mutation was found 
in the mother and all the siblings except one of the 
sisters (Figure 3).
dIscussIon
Extra-adrenal tumours comprise 10 to 20% of cases 
of PCC/PGLs and are more likely to be malignant in 
comparison to intra-adrenal tumours, 20-50% versus 
10-15%. Recent figures suggest that some 40-50% 
of patients with PGLs suffer from a hereditary form 
of the disease, but this will depend on the numbers 
of genes and also the ethnic and geographic back-
grounds of the population studied.5-7 Currently, there 
are known to be hereditary forms of the disease that 
are due to mutations of principally 11 genes: NF1, 
VHL, RET, SDH (A, B, C, D), SDHAF2, TMEM127, 
HIF2A and MAX.8-10
Succinate Dehydrogenase (SDH) is a tetrameric 
protein that is attached to the inner mitochondrial 
membrane and has 4 subunits (A, B, C and D) which 
are necessary for the functional activity of the protein. 
The enzyme catalyses succinate to fumarate in the 
Krebs cycle and contributes to electron transport; 
its main function is to link the products of the Krebs 
cycle to the electron transport system in order to 
complete glucose metabolism and ATP synthesis. The 
SDH-B gene is located on chromosome 1, spans 35.4 
Kb, contains 8 exons and encodes for a 280 amino-
acid protein.7
Mutations in the SDH-B gene are associated with 
the PGL4 syndrome. While the precise mechanism 
of tumorigenesis in carriers of the SDH-B mutation 
is unclear, it seems that increases in succinate lead 
to activation of hypoxia-inducible factors (HIF) due 
to a block of their ubiquitination: this then leads to 
deregulation of target genes implicated in cell prolif-
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eration, apoptosis and angiogenesis that finally results 
in malignant transformation.11-13 SDH-B gene mutation 
as the pathogenetic mechanism in the development 
of hereditary PGLs was originally described by Astuti 
et al in 2001;14 the following year, 2002, Neumann et 
al demonstrated that 66 out of 271 (24%) of patients 
from Germany and Poland who were classified as 
sporadic and non-syndromic PCC/PGL indeed had 
hereditary forms of the disease and had a mutation in 
one of their corresponding genes. According to their 
study, SDH-B mutation positive carriers comprised 
5.4% of the patients.3 Subsequently, Manelli et al 
showed that 32.1% of their group of 501 patients had 
a hereditary form of the disease. They also showed 
that prevalence of the hereditary form varies from 
11% to 100% in different subgroups according to 
clinical characteristics of patients such as age, loca-
tion of the tumour, the number of tumours, familial 
clustering or association of syndromic manifestation. 
SDH-B mutation carriers comprised 4.8% of their 
patients.4 The study conducted by a French group on 
445 patients with extra-adrenal PGLs demonstrated 
that 54% of their patients were SDH mutation car-
riers, those with SDH-B mutation comprising 22% 
of the cases.15
More than 90% of mutations are either a point 
mutation or small deletions or insertions in exons 
1-7. Large deletions are found in less than 10% of 
the cases. No mutation has yet been found in exon 
8. There does not appear to be a clear genotype-
phenotype correlation.2
SDH-B mutation carriers may present with either 
thoraco-abdomino-pelvic (TAP) or head-and-neck 
tumours (HNPGLs). The most frequent form is a 
solitary, catecholamine-secreting TAP tumour. The 
median age at diagnosis is 34 years, but children 
less than 10 years may also be affected. Of SDH-B 
mutation carriers, 29% develop the tumour by age 
30 years and 45% by age 40 years;16 10% of cases 
are hormonally silent, which may be due an absence 
of tyrosine hydroxylase, the rate-limiting enzyme of 
catecholamine synthesis.17 According to the study by 
Ricketts et al on 295 patients with SDH-B mutation, 
the risks of TAP and HNPGL tumour development 
were 52% and 29%, respectively, by age 60 years.18
One specific feature of SDH-B mutation carri-
ers is their tendency to develop a malignant form of 
PGL, while they may also develop tumours of other 
organs such as renal cell carcinoma19,21 or gastroin-
testinal stromal tumours.20 Neumann et al reported 
that 34% of their patients with an SDH-B mutation 
had malignant PGLs; they also reported two cases of 
renal cell carcinoma and one case of papillary thyroid 
carcinoma among their patients.21
Genetic study is essential for risk stratification, 
selection of therapeutic modalities, assessment of tu-
mour behaviour and also the evaluation of first-degree 
relatives.2,22 Currently, most large facilities specialising 
in the diagnosis and treatment of these patients will 
undertake multiple gene screening, although where 
facilities are limited the clinical characteristics of 
the patients such as age, family history, presence or 
absence of hypertension, localisation and solitary or 
multiple nature of the tumour can be helpful in the 
prioritisation of genetic screening.1,15
With regard to the current family, the mutation 
c.596-598 Del ACT (p.Tyr199del) is novel and has 
not previously been reported. As shown in Figure 3, 
the mother is involved, as are all of the siblings other 
than one sister. Evaluation of the family members 
such as collection of urine and imaging could not be 
completed because they lived in a remote area and 
were not willing to pursue the study, so we cannot be 
certain if there have been other cases with tumour 
among the family members, especially since two 
of them were hypertensive. This demonstrates the 
problems in screening and identifying patients with 
genetic disorders in societies where the economy is 
limited and specialist, clinicians and infrastructure 
are of limited availability.
The p.Tyr199 resides within a highly conserved 
iron-sulphur binding domain (4Fe-4S), which plays 
a crucial role in the mitochondrial electron transport 
system. Residue 199 is highly conserved across species 
and is in a highly conserved domain of the protein. 
Recently, an in-frame deletion of a different amino-
acid in this domain, p.Ser195del, has been reported in 
a patient with a PGL and in his affected son.23 Based 
on these data, we believe that this mutation is highly 
likely to be pathogenic. With respect to the young age 
of the family members and low penetrance rate of 
SDH-B gene mutation, which is about 25-40%, pro-
572 a. a GhaZI Et al
longed follow-up of the patient and indeed the family 
is needed for accurate interpretation.24 In general, in 
mutation-positive subjects, regular measurement of 
plasma and/or urinary metanephrines, at 6-monthly 
or yearly intervals, is the recommended follow-up 
plus annual MRI of neck, thorax and abdomen and 
radionuclide scanning. Radilobelled 123I-MIBG is 
relevant therapeutically as patients can be selected 
for 131I-MIBG therapy, but the sensitivity is not high, 
especially for metastatic tumours.25 FDG-PET is 
preferable for sensitive detection because, as the bio-
chemical derangements render these tumours highly 
inefficient in their use of glucose, they thus show a 
high degree of glucose uptake. Other radionuclides 
can be used for PET scanning but are of very limited 
availability.25
In conclusion, in this paper we present for the 
first time the clinical and genetic characteristics of 
a family with a novel SDH-B mutation from Iran.
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